{
    "medicine_id": "70bc6b31461519b281385f9121482d48112049bf",
    "platform_id": "DB05512",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v MM 093",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in autoimmune diseases psoriasis and psoriatic disorders and rheumatoid arthritis",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "M 093 Merrimack Pharmaceuticals Cambridge Massachusetts USA is a non glycosylated version of human AFP produced by recombinant DNA technology in a transgenic goat expression system hAFP is an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults and children Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy The presence of hAFP in the pregnant mother s blood has long been associated with remission of many autoimmune diseases including rheumatoid arthritis psoriasis and multiple sclerosis during the third trimester of pregnancy Current studies are assessing MM 093 s potential to improve the treatment of autoimmune disease",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}